JETCRAFT
Jetcraft , the world leader in business jet sales and acquisitions, is the launch customer for interiors specialist F/LIST’s Microshield 360 treatment program, which protects against SARS-CoV-2* and other pathogens that may otherwise live on cabin surfaces.
Additionally, Jetcraft is the first aircraft dealer using MicroShield 360. The coating system is available for all in-service aircraft purchased through the company, and will be applied to all eligible aircraft within Jetcraft’s owned inventory, beginning July 14.
Chad Anderson, president at Jetcraft, says: “MicroShield 360 is one of many ways we are expanding our offering to meet clients’ needs during Covid-19. We are pleased to be the first aircraft dealer implementing the treatment, so buyers can be confident their health is protected when purchasing directly from Jetcraft.
“Our first two jets, a Bombardier Challenger 604 and Global 5000, were treated by F/LIST on July 14. I was highly impressed by the speed of the application, which only took two hours from start to finish for a whole year of protection.”
MicroShield 360 is an antimicrobial coating system which is colorless, odorless and safe for all aircraft interiors. Owners can be reassured that it is eco-friendly, non-toxic and hypoallergenic, and won’t cause any deterioration to their aircraft cabin.
The interior application takes place in two parts: an initial disinfectant to sterilize the cabin, followed by the application of MicroShield 360, which forms a barrier of nanoscopic spikes. The spikes physically destroy germs by piercing the cell membranes, preventing them from adhering to and contaminating a surface.
An electrostatic sprayer is used to apply MicroShield 360, generating a molecular bond with the cabin surface which is equal to 40x the pull of gravity. As a result, the system is extremely abrasion resistant. Combined with regular cleaning, the treatment will ensure all surfaces are effectively self-disinfecting for 12+ months.
Sean Johnson, CEO, F/LIST Canada, adds: “In the present climate, it pays to be fastidious about your health and the cleanliness of your environment, particularly whilst traveling. With F/List partnering with Jetcraft we can bring MicroShield 360 directly to new aircraft owners, underlining how safe, controlled and comfortable travel can be when flying privately. F/List has long been known for innovative technologies that upgrade the cabin experience, and MicroShield 360 falls perfectly into that category.”
All Microshield 360 treatments are subject to Jetcraft approval. Some exclusions apply.
*SARS-CoV-2 is the virus that causes Covid-19.
ENDS
About Jetcraft
Jetcraft is the leader in international aircraft sales, marketing and ownership strategies, managing and maintaining over 20 regional offices globally. The company’s unparalleled success over more than 55 years in business aviation has earned it a world-class reputation, along with an exceptional customer base, a wide network of connections and one of the largest inventories within the industry.
For more information, please visit www.jetcraft.com
About F/LIST
F/LIST is a worldwide provider of interiors for business jets, yachts and residences, and engages more than 900 employees at eight locations in Europe, the Middle East and the Americas. Passion, reliability and a visionary spirit determine every step of this Austrian family-run business.
For more information, please visit https://f-list.at/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom